177
Management of Treatment-Resistant Schizophrenia With Clozapine Augmentation

Pwint Phyu, MD1; Emelina Arocha, MD2; Juan D. Oms, MD3; Luxhman Gunaseelan, MS-III4; Golbon Foroughi, MS-IV5; and Syed A. A. Rizvi, PhD6

1 Post Graduate Year 3, Psychiatry Department, Larkin Community Hospital, Miami, FL
2 Attending Physician, Department of Psychiatry, Larkin Community Hospital, Miami, FL
3 Program Director, Department of Psychiatry, Larkin Community Hospital, Miami, FL
4 Saba University School of Medicine, Saba, Caribbean Netherlands
5 Professor, Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL

ABSTRACT: A 44-year-old woman with a history of chronic schizoaffective disorder, epilepsy, social phobia, anxiety, and panic attacks presented with concern for “feeling anxious.” After a history, physical examination, and laboratory tests, the woman received a diagnosis of treatment-resistant schizophrenia. While clozapine is the standard therapy for schizophrenia, certain patients such as the woman in this case do not respond well to clozapine monotherapy, requiring clozapine to be augmented with other antipsychotics or antidepressants. This case outlines the unique challenges of managing patients with treatment-resistant schizophrenia, especially when they present with comorbid conditions such as epilepsy that can limit treatment options. A multi-pronged approach, including pharmacologic therapy as well as cognitive behavioral therapy, should also be considered.

FUNDING ACKNOWLEDGEMENTS: No funding.

178
Gender Differences in Prodromal Symptoms of Dementia

Richard Wallis, PhD, PMHNP1; Sheryl Bishop, PhD2; Brian Downer, PhD3; Thomas Mendez, PhD, RN, CNS4; Mukaila Raji, MD, MS, FACP5; and Aida Sapp, PhD, RN, PMHCP6

1 Nurse Practitioner, Psychiatry, Denver Health, Denver, CO
2 Professor, School of Nursing, UTMB, Galveston, TX
3 Assistant Professor, Rehabilitation Sciences, UTMB, Galveston, TX
4 Associate Professor, School of Nursing, UTMB, Galveston, TX
5 Division Director and Professor, Geriatric Medicine, UTMB, Galveston, TX
6 Professor, College of Nursing, UMHB, Belton, TX

ABSTRACT: Study Objectives: This study proposed to test the postulate that the anxiety and insomnia symptom cluster (A/I) is a predictor of dementia.

METHODS: A retrospective data analysis was conducted on the Aging, Demographics, and Memory Study (ADAMS) dataset in order to determine whether A/I symptoms or treatment were associated with subsequent dementia or cognitive impairment (DOCI). The study used logistic regression analysis and comparison of incidence rates on a sample of 249 participants.

RESULTS: There was a significant relationship between A/I symptoms and subsequent DOCI in the male gender that was not found in the total sample or in females. No association with subsequent DOCI was found for benzodiazepine usage or non-benzodiazepine A/I medication usage.

CONCLUSIONS: The gender differences identified suggest prodromal dementia phenotypes that are differentially expressed in males and females. By triangulating the approaches from multiple disciplines—such as neuroimaging and genetics—with prodromal symptoms, it is possible that reliable early prediction may be accomplished.

FUNDING ACKNOWLEDGEMENTS: No funding.

179
Dasotraline in Children With Attention Deficit Hyperactivity Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Study

Robert Goldman, PhD1; Lenard Adler, MD2; Thomas Spencer, MD3; Robert Findling, MD, MBA4; Seth C. Hopkins, PhD5; Kenneth K. Koblan, PhD6; Kaushik Sarma, MD7; Jay Hsu, PhD7; and Antony Loebel, MD8

1 Sunovion Pharmaceuticals Inc., Marlborough, MA
2 New York University Langone Medical Center, New York, NY
3 Massachusetts General Hospital, Boston, MA
4 Kennedy Krieger Institute/Johns Hopkins University, Baltimore, MD

ABSTRACT: Objectives: Once-daily dosing with dasotraline, a novel dopamine and norepinephrine reuptake inhibitor, achieves stable plasma concentrations over 24 hours with once-daily dosing. This study evaluated dasotraline in children aged 6–12 years (NCT02428088).
METHODS: Patients were randomized 1:1:1 to 6 weeks of once-daily, fixed-dose dasotraline 2 or 4 mg/day, or placebo. The primary efficacy endpoint was change from baseline (CFB) at Week 6 in ADHD Rating Scale Version IV – Home Version (ADHD RS-IV HV) total score, using a mixed model for repeated measures (MMRM) in the intent-to-treat (ITT) population. Secondary endpoints included Clinical Global Impression-Severity (CGI-S) score and safety endpoints.

RESULTS: The mean age of 342 randomized patients was 9.1 [SD: 1.9] years; 66.7% were male. Overall, 79% of patients completed the study. In the ITT population (N = 336), ADHD RS-IV HV total score improved significantly with dasotraline 4 mg/day vs placebo (least squares [LS] mean [SE] CFB at Week 6: −17.53 [± 1.31] vs −11.36 [± 1.29], respectively, p < 0.001; effect size [ES]: 0.48). Inattention and hyperactivity/impulsivity subscale scores significantly improved with 4 mg/day vs placebo at Week 6 (p = 0.001, p = 0.003, respectively). Improvement in CGI-S score was statistically significant with dasotraline 4 mg/day vs placebo (LS mean [SE] CFB at Week 6: −1.39 [± 0.12] vs −1.04 [± 0.12], respectively, p = 0.040; ES: 0.29). No significant improvement was observed on the ADHD RS-IV HV total score and the CGI-S score for dasotraline 2 mg/day vs placebo. The most frequent treatment-emergent AEs (≥25% and higher than placebo) were (2 mg/day; 4 mg/day; placebo) included: insomnia (19.6%; 3.6%, all terms combined), decreased appetite (12.6%; 21.7%; 5.2%), weight loss (5.4%; 8.7%; 0%), irritability (3.6%; 7.0%; 6.0%), nasopharyngitis (0.9%; 5.2%; 0.9%), and nausea (0%; 5.2%; 2.6%).

CONCLUSIONS: Compared with placebo, dasotraline 4 mg/day significantly improved ADHD symptoms in children, as assessed by ADHD RS-IV HV total score and inattentiveness and hyperactivity/impulsivity subscale scores. Dasotraline was generally well tolerated; most common AEs were insomnia, decreased appetite, weight loss and irritability.

FUNDING ACKNOWLEDGEMENTS: Study sponsored by Sunovion Pharmaceuticals Inc.

180 Efficacy of Dasotraline in Children With Attention Deficit Hyperactivity Disorder in a Laboratory Classroom Setting

Robert Goldman, PhD1; Ann Childress, MD2; Sharon B Wigal, PhD2; Seth C Hopkins, PhD2; Kenneth S Koblan, PhD2; Kaushik Sarma, MD1; Jay Hsu, PhD2; and Anthony Loebel, MD1

1 Sunovion Pharmaceuticals Inc., Marlborough, MA
2 Center for Psychiatry and Behavioral Medicine, Las Vegas, NV
3 AVIDA Inc., Newport Beach, CA

ABSTRACT: Objectives: Once-daily dosing with dasotraline, a novel dopamine and norepinephrine reuptake inhibitor, achieves stable plasma concentrations over 24 hours. This phase 3 study evaluated the efficacy and safety of dasotraline in children with attention deficit-hyperactivity disorder (ADHD) throughout the day, in a laboratory classroom setting (NCT02734693).

METHODS: Children (6–12 years) meeting DSM-5 criteria for ADHD were randomized to 2 weeks of dasotraline or placebo (dosed daily at home at approximately 8 PM). Following an abbreviated practice day, laboratory classroom evaluations took place at baseline and on Day 15. The primary endpoint was mean change from baseline at Day 15 in ADHD symptoms, as measured by the Swanson, Kotkin, Agler, M-Flynn, and Pelham Combined Score (SKAMP-CS), obtained from the average of 7 assessments collected across the 12-hour laboratory classroom day (12–24 hours post-dose). Secondary endpoints included SKAMP subscores obtained throughout the day at individual timepoints from 8 AM through 8 PM (12–24 hours post-dose), and measures of safety and tolerability.

RESULTS: The ITT population comprised 112 patients. Mean age was 9.5 years, 68.8% were male; 92% completed the study. Dasotraline 4 mg/day significantly improved mean SKAMP-CS versus placebo (p < 0.0001, effect size 0.85) with significant effects persisting throughout the day. Mean SKAMP subscores improved significantly versus placebo (Attention p < 0.0001, effect size 0.81; Deportment p < 0.001, effect size 0.70). Treatment-emergent adverse events were generally mild or moderate in severity; most frequent (with dasotraline 4 mg/day; placebo) included: insomnia (19.6%; 3.6%; all terms combined), decreased appetite (10.7%; 3.6%; all terms combined), decreased headache (10.7%; 8.9%; affect lability (8.9%; 7.1%), irritability (5.4%; 3.6%), postural orthostatic tachycardia syndrome (5.4%; 0%), and perceptual disturbances (5.4%; 0%).

CONCLUSIONS: In this 2-week, randomized, double-blind, laboratory classroom study in children with ADHD, once-daily dasotraline significantly improved ADHD symptoms (including deportment and attention), compared with placebo, and demonstrated sustained efficacy up to 24 hours post-dose. The most common adverse events were insomnia, decreased appetite, and headache.

FUNDING ACKNOWLEDGEMENTS: Study sponsored by Sunovion Pharmaceuticals Inc.